logo-loader
viewCreso Pharma Ltd

Creso Pharma to issue shares to Mernova Medicinal vendors; gains new substantial holder

Mernova Medicinal is scaling up cannabis production towards maximum capacity to meet growing demand from medical and recreational markets in Canada.

Creso Pharma Ltd - Creso Pharma to issue shares to Mernova Medicinal vendors; gains new substantial holder
L1 Capital became a substantial holder with a 7.35% stake in Creso on June 23, 2020

Creso Pharma Ltd (ASX:CPH), (FRA:1X8) had achieved its second milestone in respect of its 2017 acquisition of Mernova Medicinal Inc in February 2020.

Upon achievement of the second milestone, a cash payment of C$800,000 became due and payable to the Mernova vendors.

Creso has today reached an agreement with the vendors to settle part of the debt in respect of the second milestone payment through the issuance of ~15 million shares at a deemed issue price of 5 cents per share.

Licensed Canadian producer

Mernova is ramping up cannabis production towards maximum capacity ahead of the launch of its premium retail products.

The licensed producer based in Nova Scotia, Canada, has been focusing on streamlining its operations to meet growing demand from medical and recreational markets in Canada after it received its sales licence from Health Canada in May.

These optimisation changes have streamlined production and delivered tangible improvements to cannabis quality, with increased yields expected over the coming months.

New substantial holder

L1 Capital has become a substantial holder with a 7.35% stake in Creso on June 23, 2020 after acquiring more than 25 million shares for its Global Opportunites Master Fund.

L1 Capital is an independent global investment manager owned by its staff. All members of the investment team are invested alongside clients.

Quick facts: Creso Pharma Ltd

Price: 0.03 AUD

ASX:CPH
Market: ASX
Market Cap: $10.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

4 weeks ago

2 min read